LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Anavex Life Sciences Corp

Geschlossen

BrancheGesundheitswesen

9.11 0.77

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.88

Max

9.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

915K

-11M

EPS

-0.132

Angestellte

42

EBITDA

106K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+213.53% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

34M

762M

Vorheriger Eröffnungskurs

8.34

Vorheriger Schlusskurs

9.11

Nachrichtenstimmung

By Acuity

50%

50%

156 / 381 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juni 2025, 18:52 UTC

Ergebnisse

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20. Juni 2025, 16:15 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

21. Juni 2025, 08:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

21. Juni 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

21. Juni 2025, 08:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

20. Juni 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

20. Juni 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

20. Juni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Juni 2025, 20:13 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20. Juni 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20. Juni 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20. Juni 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20. Juni 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20. Juni 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20. Juni 2025, 17:50 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20. Juni 2025, 17:35 UTC

Akquisitionen, Fusionen, Übernahmen

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20. Juni 2025, 17:30 UTC

Market Talk
Ergebnisse

Adobe's AI Headwinds Seen Fading -- Market Talk

20. Juni 2025, 17:03 UTC

Ergebnisse

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20. Juni 2025, 16:50 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

20. Juni 2025, 16:50 UTC

Market Talk
Ergebnisse

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20. Juni 2025, 16:44 UTC

Akquisitionen, Fusionen, Übernahmen

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20. Juni 2025, 16:40 UTC

Market Talk
Ergebnisse

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20. Juni 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

20. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Juni 2025, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit: ULI and UVA Are Expected to Merge in 2026

20. Juni 2025, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20. Juni 2025, 16:05 UTC

Market Talk

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20. Juni 2025, 15:56 UTC

Market Talk
Ergebnisse

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20. Juni 2025, 15:26 UTC

Market Talk

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20. Juni 2025, 15:25 UTC

Akquisitionen, Fusionen, Übernahmen

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

213.53% Vorteil

12-Monats-Prognose

Durchschnitt 28.5 USD  213.53%

Hoch 42 USD

Tief 15 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

8.275 / 9.312Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

156 / 381 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.